HC Wainwright reaffirmed their buy rating on shares of Lion Biotechnologies, Inc. (NASDAQ:IOVA) in a research report released on Thursday. HC Wainwright currently has a $16.00 price target on the biotechnology company’s stock.
IOVA has been the subject of several other research reports. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of Lion Biotechnologies and gave the stock a buy rating in a research report on Friday, August 18th. Chardan Capital upped their price objective on shares of Lion Biotechnologies from $18.00 to $20.00 and gave the stock a buy rating in a research report on Thursday, May 4th. Zacks Investment Research cut shares of Lion Biotechnologies from a buy rating to a hold rating in a research report on Thursday, August 3rd. Rodman & Renshaw initiated coverage on shares of Lion Biotechnologies in a research report on Wednesday, May 10th. They set a buy rating and a $13.00 price objective for the company. Finally, Cowen and Company reaffirmed a buy rating on shares of Lion Biotechnologies in a research report on Tuesday, June 6th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Lion Biotechnologies currently has an average rating of Buy and an average target price of $13.88.
Lion Biotechnologies (NASDAQ:IOVA) traded up 4.35% during trading on Thursday, hitting $6.00. 1,507,385 shares of the stock were exchanged. The stock’s market capitalization is $376.12 million. Lion Biotechnologies has a 52 week low of $4.45 and a 52 week high of $8.61. The firm has a 50-day moving average of $5.59 and a 200-day moving average of $6.45.
COPYRIGHT VIOLATION WARNING: “Lion Biotechnologies’ (IOVA) Buy Rating Reiterated at HC Wainwright” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/09/03/lion-biotechnologies-iova-buy-rating-reiterated-at-hc-wainwright.html.
A number of large investors have recently bought and sold shares of the company. AXA bought a new stake in Lion Biotechnologies during the second quarter worth about $4,989,000. Wells Fargo & Company MN bought a new position in shares of Lion Biotechnologies in the second quarter worth about $528,000. Franklin Resources Inc. bought a new position in shares of Lion Biotechnologies in the second quarter worth about $37,844,000. Atlantic Trust Group LLC bought a new position in shares of Lion Biotechnologies in the second quarter worth about $316,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Lion Biotechnologies in the second quarter worth about $8,006,000. 76.00% of the stock is owned by institutional investors and hedge funds.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.